vs

Side-by-side financial comparison of Canaan Inc. (CAN) and Neuphoria Therapeutics Inc. (NEUP). Click either name above to swap in a different company.

Canaan Inc. is the larger business by last-quarter revenue ($20.8M vs $15.0M, roughly 1.4× Neuphoria Therapeutics Inc.). Neuphoria Therapeutics Inc. runs the higher net margin — 75.1% vs -18.4%, a 93.5% gap on every dollar of revenue.

Canaan Inc., doing business as Canaan Creative and known simply as Canaan, is a Singapore-based computer hardware manufacturer. Established in 2013 by N.G. Zhang, Canaan specializes in Blockchain servers and ASIC microprocessors for use in bitcoin mining.

Neuphoria Therapeutics Inc is a clinical-stage biopharmaceutical company focused on researching and developing innovative targeted therapies for unmet medical needs in neurological and psychiatric conditions, including anxiety, treatment-resistant depression, and other central nervous system disorders. Its core R&D efforts prioritize delivering safer, more effective treatment options for patient groups with limited existing care alternatives.

CAN vs NEUP — Head-to-Head

Bigger by revenue
CAN
CAN
1.4× larger
CAN
$20.8M
$15.0M
NEUP
Higher net margin
NEUP
NEUP
93.5% more per $
NEUP
75.1%
-18.4%
CAN

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
CAN
CAN
NEUP
NEUP
Revenue
$20.8M
$15.0M
Net Profit
$-3.8M
$11.3M
Gross Margin
99.9%
Operating Margin
-15.9%
79.8%
Net Margin
-18.4%
75.1%
Revenue YoY
Net Profit YoY
EPS (diluted)
$-0.05
$6.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CAN
CAN
NEUP
NEUP
Q4 25
$20.8M
Q3 25
$13.8M
Q2 25
$11.4M
Q1 25
$15.0M
Q3 24
$10.2M
Q2 24
$4.8M
Net Profit
CAN
CAN
NEUP
NEUP
Q4 25
$-3.8M
Q3 25
$-1.5M
Q2 25
$-11.9M
Q1 25
$11.3M
Q3 24
$-10.4M
Q2 24
$-5.4M
Gross Margin
CAN
CAN
NEUP
NEUP
Q4 25
99.9%
Q3 25
99.9%
Q2 25
99.9%
Q1 25
Q3 24
99.9%
Q2 24
99.8%
Operating Margin
CAN
CAN
NEUP
NEUP
Q4 25
-15.9%
Q3 25
-27.0%
Q2 25
-45.5%
Q1 25
79.8%
Q3 24
-77.2%
Q2 24
-193.9%
Net Margin
CAN
CAN
NEUP
NEUP
Q4 25
-18.4%
Q3 25
-11.0%
Q2 25
-104.4%
Q1 25
75.1%
Q3 24
-102.7%
Q2 24
-112.3%
EPS (diluted)
CAN
CAN
NEUP
NEUP
Q4 25
$-0.05
Q3 25
$-0.02
Q2 25
$-0.25
Q1 25
$6.55
Q3 24
Q2 24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CAN
CAN
NEUP
NEUP
Cash + ST InvestmentsLiquidity on hand
$17.0M
Total DebtLower is stronger
$6.2M
Stockholders' EquityBook value
$52.4M
$26.0M
Total Assets
$92.5M
$30.7M
Debt / EquityLower = less leverage
0.12×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CAN
CAN
NEUP
NEUP
Q4 25
Q3 25
Q2 25
Q1 25
$17.0M
Q3 24
Q2 24
Total Debt
CAN
CAN
NEUP
NEUP
Q4 25
$6.2M
Q3 25
$6.2M
Q2 25
$6.2M
Q1 25
Q3 24
Q2 24
Stockholders' Equity
CAN
CAN
NEUP
NEUP
Q4 25
$52.4M
Q3 25
$44.7M
Q2 25
$33.8M
Q1 25
$26.0M
Q3 24
$43.6M
Q2 24
$56.8M
Total Assets
CAN
CAN
NEUP
NEUP
Q4 25
$92.5M
Q3 25
$81.7M
Q2 25
$78.0M
Q1 25
$30.7M
Q3 24
$69.3M
Q2 24
$73.7M
Debt / Equity
CAN
CAN
NEUP
NEUP
Q4 25
0.12×
Q3 25
0.14×
Q2 25
0.18×
Q1 25
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CAN
CAN
NEUP
NEUP
Operating Cash FlowLast quarter
$11.5M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
1.02×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CAN
CAN
NEUP
NEUP
Q4 25
Q3 25
Q2 25
Q1 25
$11.5M
Q3 24
Q2 24
Cash Conversion
CAN
CAN
NEUP
NEUP
Q4 25
Q3 25
Q2 25
Q1 25
1.02×
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons